Inhibition of the late phase reaction to anti-human IgE in man by oral tranexamic acid.
Pharmacological modulation of the immediate and late phase reaction (LPR) to anti-human IgE was further investigated in a double-blind cross-over study. Tranexamic acid (AMCA) 1 g t.i.d. 24 h prior to and following intradermal injection of anti-IgE produced an approximate 40% inhibition of the LPR (P less than 0.01) without affecting the early response as compared with placebo in 10 volunteers. Antagonistic effect on activation of fibrinolysis and possibly the complement system is suggested as a possible mode of action.
D000888:Antibodies, Anti-Idiotypic / Q000276:immunology; D002986:Clinical Trials as Topic; D003509:Cyclohexanecarboxylic Acids / Q000494:pharmacology*; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007073:Immunoglobulin E / Q000276:immunology*; D012882:Skin Tests; D014148:Tranexamic Acid / Q000494:pharmacology*
D000888:Antibodies, Anti-Idiotypic; D003509:Cyclohexanecarboxylic Acids; D007073:Immunoglobulin E; D014148:Tranexamic Acid